What has to go right for Isomorphic to be worth $50 billion

Isomorphic Labs is in talks to raise about $5 billion at a valuation near $50 billion, and it has not yet put a drug into a person. Biogen sold $10.3 billion of medicines over the past year and is worth $37.5 billion.

The price makes sense only if Isomorphic's drugs work in patients far more often than the industry's, and the industry's record is getting worse: the share of drugs entering phase I that reach approval fell from 10.4% to 6.7% between 2014 and 2024. A model can score a molecule as a success and still lose it in patients, pelacarsen cut Lp(a) by up to 80% and then failed an outcome trial of 8,323 people.

Four things have to go right: Isomorphic has to keep enough of its best molecules to matter and pay for their trials itself; its drugs have to work far more often; its models have to stay ahead of ones anyone can license, since AlphaFold 3 was matched by free models within a year; and its investors have to wait years for evidence only patients can produce.